Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia

References

• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation20021063143342112485966
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJLichtensteinAH2013ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelinesJ Am Coll Cardiol Epub1172013
   Google Scholar
• BrunzellJDDavidsonMFurbergCDLipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology FoundationDiabetes Care20083181182218375431
   PubMed Web of Science ®Google Scholar
• DavidsonMHBallantyneCMJacobsonTAClinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialistsJ Clin Lipidol2011533836721981835
   PubMed Web of Science ®Google Scholar
• GenestJMcPhersonRFrohlichJ2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendationsCan J Cardiol20092556757919812802
   PubMed Web of Science ®Google Scholar
• CatapanoALReinerŽDe BackerGESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Atherosclerosis201121714421722901
   PubMed Web of Science ®Google Scholar
• BoekholdtSMArsenaultBJMoraSAssociation of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysisJAMA20123071302130922453571
   PubMed Web of Science ®Google Scholar
• IngelssonESchaeferEJContoisJHClinical utility of different lipid measures for prediction of coronary heart disease in men and womenJAMA200729877678517699011
   PubMed Web of Science ®Google Scholar
• LiuJSemposCTDonahueRPDornJTrevisanMGrundySMNon-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart diseaseAm J Cardiol2006981363136817134630
   PubMed Web of Science ®Google Scholar
• PischonTGirmanCJSacksFMRifaiNStampferMJRimmEBNon-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in menCirculation20051123375338316316964
   PubMed Web of Science ®Google Scholar
• RobinsonJGWangSSmithBJJacobsonTAMeta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease riskJ Am Coll Cardiol20095331632219161879
   PubMed Web of Science ®Google Scholar
• SnidermanADWilliamsKContoisJHA meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular riskCirc Cardiovasc Qual Outcomes2011433734521487090
   PubMed Web of Science ®Google Scholar
• DavidsonMHReducing residual risk for patients on statin therapy: the potential role of combination therapyAm J Cardiol2005963K13K
   PubMed Web of Science ®Google Scholar
• GuytonJRGoldbergACKreisbergRASprecherDLSuperkoRO’ConnorCMEffectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemiaAm J Cardiol1998827377439761083
   PubMed Web of Science ®Google Scholar
• The Coronary Drug Project Research GroupClofibrate and niacin in coronary heart diseaseJAMA19752313603811088963
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoX-QChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med20013451583159211757504
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJLeeJKGraceKAArterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation20041103512351715537681
   PubMed Web of Science ®Google Scholar
• The AIM-HIGH InvestigatorsNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med20113652255226722085343
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative GroupHPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEur Heart J2013341279129123444397
   PubMed Web of Science ®Google Scholar
• BallantyneCMAndrewsTCHsiaJAKramerJHShearCCorrelation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levelsAm J Cardiol20018826526911472705
   PubMed Web of Science ®Google Scholar
• BallantyneCMRaichlenJSCainVAStatin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trialJ Am Coll Cardiol20085262663218702965
   PubMed Web of Science ®Google Scholar
• Charlton-MenysVBetteridgeDJColhounHTargets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)Clin Chem20095547348019147732
   PubMed Web of Science ®Google Scholar
• IdrisITateHAhmadAMcCormackTConcordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: post-hoc analyses from the UK InPractice studyJ Clin Lipidol2011531632321784378
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLTomassiniJETershakovecAMCorrelation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial)Am J Cardiol200910454855319660610
   PubMed Web of Science ®Google Scholar
• FarnierMTaggartWDongQLinJShahABrudiPInfluence of simvastatin, fenofibrate and/or ezetimibe on correlation of LDL and non-HDL cholesterol with apolipoprotein B in mixed dyslipidemic patientsJ Clin Lipidol2011517918721600523
   PubMed Web of Science ®Google Scholar
• FarnierMGuytonJRJensenEPolisABJohnson-LevonasAOBrudiPEffects of Ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non HDL cholesterol in patients with primary hypercholesterolemiaAtherosclerosis201322941542223880197
   PubMed Web of Science ®Google Scholar
• GleimGBallantyneCMLiuNEfficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemiaBr J Cardiol2009169097
   Google Scholar
• FriedewaldWTLevyRIFredricksonDSEstimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugeClin Chem1972184995024337382
   PubMed Web of Science ®Google Scholar
• MaccubbinDBaysHEOlssonAGLipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemiaInt J Clin Pract2008621959197019166443
   PubMed Web of Science ®Google Scholar